Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe

Neurology

Volumn 79, Issue 7, 2012, Pages 642-650

  Samieri, Cécilia ^a,b   Maillard, Pauline ^c,d,e   Crivello, Fabrice ^b,d,f   Proust Lima, Cécile ^a,b   Peuchant, Evelyne ^a,g   Helmer, Catherine ^a,b   Amieva, Helene ^a,b   Allard, Michele ^b,c,h,i   Dartigues, Jean Francois ^a,b   Cunnane, Stephen C ^j   Mazoyer, Bernard M ^b,d,f   Barberger Gateau, Pascale ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS   (France)

^d DIF   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f Groupe d'Imagerie Neurofonctionnelle   (France)

^g HÔPITAL SAINT ANDRÉ   (France)

^h CNRS UB1 UB2 Unit   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE SHERBROOKE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID;

AGED; AMYGDALOID NUCLEUS; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; DEPRESSION; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GRAY MATTER; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE ATROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPUS; PRIORITY JOURNAL; SEMANTIC MEMORY;

EID: 84866125224     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318264e394     Document Type: Article

References (40)

1. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, longchain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 2009;5:140 -152.
2. Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009;48:239 -256.
3. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010;6:456-464.
4. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, doubleblind, controlled trial. Am J Clin Nutr 2010;91:1725-1732.
5. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903-1911.
6. Tan ZS, Harris WS, Beiser AS, et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012;78:658-664.
7. Three-City Study Group. Vascular Risk factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 2003;22:316 -325.
8. The FIL Methods Group. SPM8 Manual. London, UK, 2010. Available at: http://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf. Accessed June 2012.
9. Lemaitre H, Crivello F, Dufouil C, et al. No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 2005;24: 1205-1213.
10. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973;123:467-470.
13. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008;64:492- 498.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
15. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385- 401.
16. Berkman LF, Berkman CS, Kasl S, et al. Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol 1986;124:372-388.
17. Fuhrer R, Rouillon F. La Version Française de l'Échelle CES-D (Center for Epidemiologic Studies-Depression Scale): description et traduction de l'échelle d'autoévaluation. Psychiatr Psychobiol 1989;4:163-166.
18. Samieri C, Feart C, Letenneur L, et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 2008;88:714 -21.
19. Proust-Lima C, Dartigues JF, Jacqmin-Gadda H. Misuse of the linear mixed model when evaluating risk factors of cognitive decline. Am J Epidemiol 2011;174:1077-1088.
20. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
21. Proust C, Jacqmin-Gadda H, Taylor JM, Ganiayre J, Commenges D. A nonlinear model with latent process for cognitive evolution using multivariate longitudinal data. Biometrics 2006;62:1014 -1024.
22. Virtanen JK, Siscovick DS, Longstreth WT Jr, Kuller LH, Mozaffarian D. Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. Neurology 2008;71:439-446.
23. Bowman GL, Silbert LC, Howieson D, et al. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 2012;78:241-249.
24. Conklin SM, Gianaros PJ, Brown SM, et al. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett 2007;421:209 -212.
25. Samieri C, Feart C, Proust-Lima C, et al. Omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging 2011;32: 2317.e13- e22.
26. Feart C, Peuchant E, Letenneur L, et al. Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr 2008;87:1156 -1162.
27. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006;163:969 -978.
28. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009;28:525-542.
29. Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005;64:1520 -1524.
30. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57- 62.
31. Horinek D, Varjassyova A, Hort J. Magnetic resonance analysis of amygdalar volume in Alzheimer's disease. Curr Opin Psychiatry 2007;20:273-277.
32. Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. Neurobiol Aging 2011;32: 1733-1741.
33. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, Mc-Donald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009;6:347-361.
34. Murphy EA, Holland D, Donohue M, et al. Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls. Neuroimage 2010;53: 1310-1317.
35. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455:894 -902.
36. Hamilton JP, Siemer M, Gotlib IH. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiatry 2008;13:993-1000.
37. Suslow T, Konrad C, Kugel H, et al. Automatic moodcongruent amygdala responses to masked facial expressions in major depression. Biol Psychiatry 2010;67:155-160.
38. Windischberger C, Lanzenberger R, Holik A, et al. Areaspecific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 2010;49:1161-1170.
39. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008;47:348-380.
40. Harald K, Salomaa V, Jousilahti P, Koskinen S, Vartiainen E. Non-participation and mortality in different socioeconomic groups: the FINRISK population surveys in 1972-92. J Epidemiol Community Health 2007;61:449 - 454.